Published in Science on December 14, 2007
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev (2013) 3.21
Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science (2010) 3.20
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol (2012) 3.11
Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol (2013) 3.02
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc Natl Acad Sci U S A (2009) 2.85
Proteopedia - a scientific 'wiki' bridging the rift between three-dimensional structure and function of biomacromolecules. Genome Biol (2008) 2.68
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer (2009) 2.39
Annotating cancer variants and anti-cancer therapeutics in reactome. Cancers (Basel) (2012) 2.35
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell (2008) 2.32
Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res (2010) 2.30
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer (2015) 2.10
Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 2.09
Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci U S A (2012) 2.04
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett (2010) 1.89
Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J (2009) 1.88
Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res (2009) 1.86
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell (2013) 1.74
AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS One (2014) 1.62
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene (2010) 1.56
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clin Cancer Res (2015) 1.53
Rapamycin and mTOR kinase inhibitors. J Chem Biol (2008) 1.51
Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110α. Structure (2011) 1.48
Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol (2009) 1.47
Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci U S A (2009) 1.46
Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci U S A (2008) 1.46
Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer (2008) 1.42
Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α. FEBS J (2015) 1.38
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle (2008) 1.35
Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein. Proc Natl Acad Sci U S A (2010) 1.34
A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A (2010) 1.23
Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle (2010) 1.22
PI3Kα inhibitors that inhibit metastasis. Oncotarget (2010) 1.19
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet (2012) 1.19
A site-specific, multiplexed kinase activity assay using stable-isotope dilution and high-resolution mass spectrometry. Proc Natl Acad Sci U S A (2009) 1.17
The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol (2010) 1.16
Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem (2009) 1.15
Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival. Mol Cell Biol (2011) 1.14
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene (2011) 1.14
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res (2010) 1.10
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem Biol (2008) 1.09
RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling. J Biol Chem (2009) 1.06
Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85alpha Src homology-2 domains. Proc Natl Acad Sci U S A (2011) 1.06
Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A (2015) 1.06
Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv Biol Regul (2012) 1.05
A beta version of life: p110β takes center stage. Oncotarget (2010) 1.01
BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity. Mol Cell (2014) 1.00
Advances in the targeted therapy of liposarcoma. Onco Targets Ther (2015) 0.99
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res (2011) 0.98
Statistical method on nonrandom clustering with application to somatic mutations in cancer. BMC Bioinformatics (2010) 0.97
The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Mol Cancer Res (2015) 0.96
S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS One (2009) 0.95
Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs. Mol Cancer Res (2009) 0.94
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res (2014) 0.94
Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. Nat Genet (2015) 0.94
Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochem J (2008) 0.94
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer (2013) 0.93
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res (2014) 0.93
Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods. ChemMedChem (2011) 0.93
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro Oncol (2010) 0.92
Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol (2010) 0.91
E17K substitution in AKT1 in prostate cancer. Br J Cancer (2010) 0.91
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) (2014) 0.91
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget (2015) 0.90
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. J Carcinog Mutagen (2013) 0.89
Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha. ACS Chem Biol (2009) 0.89
PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press) (2015) 0.88
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk (2014) 0.88
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Structural effects of oncogenic PI3Kα mutations. Curr Top Microbiol Immunol (2010) 0.87
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol (2016) 0.87
Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci (2014) 0.86
Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem (2013) 0.86
P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP. Cell Death Dis (2014) 0.86
The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets (2008) 0.86
PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations. Proteins (2009) 0.86
Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data. PLoS One (2013) 0.86
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
International network of cancer genome projects. Nature (2010) 20.35
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78
The antisense transcriptomes of human cells. Science (2008) 6.29
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42